

Drug and Therapeutics Committee – Minutes – approved	
---	--

Date / Time	14 th May 2015
Venue	The Committee Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Wendy Hornsby, Senior Pharmacy Technician.
Quorate: Yes / No	Yes

Attendance	Dr M Miller, Senior Principal Pharmacist, Interface Mr P O'Brien, Deputy Chief Pharmacist Prof M Lind, Vice Chair, Professor of Oncology Mrs C Grantham, Medicines Management Nurse Dr E Williamson, Consultant Microbiologist Dr O Ogunbambi, Consultant Rheumatologist Mr K McCorry, Local Pharmaceutical Advisor, ER CSU
-------------------	---

Apologies	Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mrs K Beal, Lay Trust Member Mrs J Lyon, Head of Medicines Management, North Yorks and Humber CSU Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2015.05.01	Apologies	As above. The committee were informed that Mrs Beal had resigned from the committee as Lay Trust Member.	DC to be asked to begin recruitment process of new lay member		DC	6/15	
2015.05.02	Declarations of Interest	There were no declarations of interest.	Noted.	No further action			5/15
2015.05.03	Minutes of the previous meeting	The minutes were accepted as a true record.	Noted	No further action			5/15
2015.05.05	Action Tracker	HERPC Minutes KMc reported that after investigations Ezetimibe prescribing was not deemed to be an issue with secondary care specialists and therefore AM does not need to write to cardiology. Minutes of the Previous Meeting Chronic cough has been amended to bronchorrea Review of Diclofenac Use Diclofenac has been removed from ward stock lists NICE Guidance MM to check if SG has written to diabetes team re TA 336 and Empagliflozins place in pathway MHRA DSU	Action complete Action complete Action complete MM to discuss with diabetes team	No further action No further action No further action MM/SG to feedback next time	KMc/AM WH SG SG/MM	 5/15	5/15 5/15 5/15

		<p>Ferumoxytol has been removed from formulary.</p> <p>Minutes from HERPC "via IFR only " has been added to Eflornithine and Ketamine entries of formulary</p> <p>Correspondence Received Fosfomycin injection has been removed from the unlicensed list and added to formulary.</p> <p>D&T Attendance To be raised at surgery governance and FU to discuss with anaesthetists. SG and FU not in attendance, stay on tracker and discuss next time.</p> <p>Any Other Business ML/SG to request acute pain team discuss use of opiate conversion chart. ML to discuss with Dr Sampu.</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Feedback next time</p> <p>ML to discuss with Dr Sampu</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>SG/FU to feedback next time</p> <p>ML to feedback next time</p>	<p>WH</p> <p>WH</p> <p>WH</p> <p>SG/FU</p> <p>ML</p>	<p></p> <p></p> <p></p> <p>5/15</p> <p>5/15</p>	<p>5/15</p> <p>5/15</p> <p>5/15</p> <p></p>
2015.05.05	New Product Requests	<p>Secukinumab – Dr Walton Due to good clinical evidence the product was approved. Dermatology to be asked to produce flowchart to demonstrate place in treatment pathway.</p>	<p>Approved</p>	<p>AM to write to applicant</p> <p>WH to update formulary</p> <p>POB to ask dermatology to product flow chart</p>	<p>AM</p> <p>WH</p> <p>POB</p>	<p>6/15</p> <p>6/15</p> <p>6/15</p>	
2015.05.06	NICE Guidance	<p>No NICE guidance was published in April</p>	<p>Noted</p>	<p>No further action</p>			<p>5/15</p>

2015.05.07	MHRA Drug Safety update	April 15 Hydroxyzine dose – POB to write to renal and dermatology to highlight issue. Codeine – has already been withdrawn for use in under 12s by HEY	Noted	MM to write to renal and dermatology	MM	6/15	
2015.05.08	IFR flow chart	Due to recent issues on chairs approval POB has drawn up a flowchart to demonstrate process to request/approve further approvals. The flowchart show that sign off is required by HG medical director but the committee felt that this should be checked with the chief medical officer.	Agreed to escalate to OQC for approval	POB to escalate to OQC	POB	6/15	
2015.05.09	Antibiotic Formulary	<ul style="list-style-type: none"> • Adult Antimicrobial Formulary • Glycopeptide Antibiotics in Adults • Linezolid Guidelines Documents have all been approved by ACAT. A query was raised around the prescribing of co-trimoxazole for the treatment of pneumonia in the elderly as DME guideline recommends use of co-trimoxazole but adult guideline recommends use of penicillin and macrolide combination. It was agreed that Sepsis chart would be update with a separate amendment giving guidance on how to treat elderly patients.	All approved	AM to write to ACAT an inform them of committees decision	AM	6/15	
2015.05.10	Unlicensed List	The unlicensed list and the temporary unlicensed list have both been updated.	Agreed to add to website	WH to update website	WH	6/15	
2015.05.11	Correspondence Received	Urgotul SSD – currently on formulary for use by vascular specialist nurse only , dressings group requested that formulary be update to include use by tissue viability nurses aswell.	Change approved	WH to update formulary	WH	6/15	

		Pembrolizumab – NHSE specialist circular published to show Pembrolizumab has been approved by the Early Access to Medicines Scheme (EAMS).	Dr Maravayas to submit a new product request form	ML to speak to Dr Maravayas	ML	6/15	
2015.05.10	Chairs Approvals	No chairs approvals this month	Noted	No further action			5/15
2015.05.13	Issues to escalate to Operational Quality Committee	IFR flow chart			POB	6/15	
2015.05.14	Any other Business	POB informed the committee that the trust were bidding to become a Hepatitis C specialist centre, previously the committee has approved a new product request for sofosbuvir POB asked the committee if they would agree to the use of daclatasvir which is used in combination with sofosbuvir to aid in the bid. This is in line with NHS England commissioning policy.	Committee agree to the addition of daclatasvir to the formulary	WH to update formulary	WH	6/15	
2015.05.15	Date and Time of Next Meeting	Thursday 11 th June 2015, 8.15am – 9.30am. The Committee Room, Alderson House, HRI					